Within the framework of the agreement, Jarlen Capital will actively identify, contact and process potential licensees and other commercial partners. The assignment also includes establishing relevant contacts and contributing to advancing commercial dialogues towards possible licensing, collaboration or other commercial transactions.

The agreement is performance-based and does not involve any fixed or ongoing compensation to Jarlen Capital. Compensation is only paid if Jarlen Capital''s efforts lead to a completed commercial transaction where Aptahem receives an upfront payment. In such a case, compensation is paid in the form of a pre-agreed success fee based on the upfront payment that accrues to Aptahem.

CEO Mikael Lindstam comments:

"This agreement strengthens our commercial development by adding additional capacity and network in the work of identifying and developing relevant partner dialogues. Jarlen Capital receives a clear mandate to actively work towards potential licensees and other commercial partners. At the same time, the model is completely results-based, which means that costs for Aptahem only arise when the work contributes to a completed transaction and an actual upfront payment to the Company."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com